Back to the Top
Dear All,
Particulate Novel Drug Delivery systems like nanoparticles and
nanocapsules are the effective techniques in their own way.
For a anti-cancer drug delivery systems, particulate systems were found
to be effective. With nano technology, drug targeting can be easily done
which enhances certain PK parameters of drug.
So designing a NDDS with PK considerations is an effective way out for
anti cancer drugs.
I would like to know what kind of anti-cancer agents should be
considered
for such PK based nanoparticular drug delivery systems.
What drug characteristic should i look for?
Is it necessary to use cancer animal models for the evaluation of such
studies or whether it is feasible using normal animal models like
routein
PK studies with rats or mice?
My considerations for this work are mainly based on enhancement of site
specific bioavailability with overall systemic bioavailability of the
anti-cancer drug.
have a nice day
K.Prashant
Kole Prashant, M.Pharm (Ph.D)
Faculty,
Formulation and Pharmacokinetics Laboratory
Pharmacy Group,
Birla Institute of Technology and Science, Pilani
Rajasthan, 333031
Phone: (O) 01596-245074-Ext-458
Fax: 01596-244183
Alt.Email: prashantkole.-at-.rediffmail.com,plkole.-a-.yahoo.com
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)